Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders

This is a clinical trial of Microbiota Transplant Therapy (MTT) for adults with autism spectrum disorders (ASD) who have gastrointestinal problems. Previous research has shown that individuals with ASD have a low diversity of gut bacteria, and low diversity is generally associated with poor gastrointestinal (GI) health. We previously found that MTT therapy for children with ASD and GI symptoms was helpful in reducing their GI symptoms, reducing their ASD symptoms, and increasing their diversity of gut bacteria. This clinical trial will investigate the hypothesis that MTT therapy will be helpful for adults with ASD who have GI symptoms.

NCT Number	NCT03408886
Lead Sponsor	Arizona State University
Conditions	Autism Spectrum Disorder, Gastrointestinal Disorder
Enrollment	55 participants
Start Date	2018-01-04
Primary Completion	2022-04-15 (estimated)
Study Completion	2024-12-15 (estimated)
Updated on ClinicalTrials.gov	2023-01-09